Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jazz Pharmaceuticals
Pharma
Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH
If approved, Lumryz would add more pressure to Jazz’s blockbuster Xywav, which counts idiopathic hypersomnia as its main growth driver.
Angus Liu
May 12, 2026 11:45am
JPM26: Jazz inks $200M priority review voucher sale
Jan 14, 2026 3:55pm
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
Jan 6, 2026 3:25pm
Zymeworks pivots to become 'royalty-driven' drugmaker
Nov 18, 2025 8:25am
Jazz chalks up another win with HER2 drug Ziihera
Nov 17, 2025 10:28am
To enter sleep market, Alkermes forks over $2.1B for Avadel
Oct 22, 2025 12:04pm
